Phillips G, Guilford WJ, Buckman BO, Davey DD, Eagen KA, Koovakkat S, Liang A, McCarrick M, Mohan R, Ng HP, Pinkerton M, Subramanyam B, Ho E, Trinh L, Whitlow M, Wu S, Xu W, Morrissey MM. Design, synthesis, and activity of a novel series of factor Xa inhibitors: optimization of arylamidine groups.
J Med Chem 2002;
45:2484-93. [PMID:
12036356 DOI:
10.1021/jm0200660]
[Citation(s) in RCA: 18] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
A novel series of diaryloxypyridines have been designed as selective nanomolar factor Xa (fXa) inhibitors for use as anticoagulants. In this paper, we describe our efforts to identify an additional interaction and a replacement for the distal amidine group that binds in the S3/S4 pocket of fXa. Introduction of a hydroxyl group para to the proximal amidine group increases the potency vs fXa by 1-2 orders of magnitude, which is the result of a hydrogen bond to Ser195 of the catalytic triad. A methyl imidazoline and a dimethylamide are good alternatives for the second amidine. These substitutions have increased the selectivity vs the related serine proteases trypsin and thrombin. The synthesis, in vitro activity, and hypothetical modes of binding to fXa based on trypsin crystallographic data are outlined.
Collapse